Global News Roundup: Q1 2022
Windrose Consulting Group, Global News Roundup: Q1 2022
We are pleased to launch the second edition of our quarterly Windrose Consulting Group: Global News Roundup for Q1 2022
In this edition, we look at many key changes in the Global Life Sciences industry, such as: Pan-European HTA regulation that launched January 2022; Mexico cutting the order of medicines through UNOPS for 2022 after shortage problems; and the UK having Lumykras (sotorasib) as the first drug to complete the UK’s Innovative Licensing and Access Pathway; plus more coverage from around the world.
Strategic guidance for Life Sciences.
Founded in 2015, Windrose Consulting Group is a privately-held global strategy firm that partners with life science companies to maximize the commercial value of their products—so they can meet today’s most critical healthcare needs. We work across a broad range of products and disease areas with services that include product commercialization, pricing and market access and value communication. We’re committed to helping companies succeed in bringing innovations to market that enhance people’s lives. We work globally and have three offices, based in Philadelphia (US), London (UK) and Lucerne (Switzerland).